[Intravesical adjuvant regimen of epitubicin for intermediate risk NMIBC: Feasability study from CC-AFU vessie]. Rollin P, Xylinas E, Lanz C, Audenet F, et al. Prog Urol 2022;32:326-331.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Rollin P, Xylinas E, Lanz C, Audenet F, et al. [Intravesical adjuvant regimen of epitubicin for intermediate risk NMIBC: Feasability study from CC-AFU vessie]. Prog Urol 2022;32:326-331.
PMID: 35151544